Streetbeat News

Analyst Ratings

ARWR

HC Wainwright & Co. has reiterated its Buy rating on Arrowhead Pharma, maintaining a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 7:04 pm

SKT

Analysts have mixed views on Tanger (NYSE:SKT) with recent evaluations showing a shift towards a more bullish sentiment. The average 12-month price target has increased by 7.43% to $31.8. Tanger has shown strong revenue growth but faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 7:01 pm

SPT

Sprout Social (NASDAQ:SPT) has been evaluated by 7 analysts over the past three months, with opinions ranging from bullish to bearish. The average 12-month price target is $44.29, a decrease from the previous $48.67. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Sprout Social has shown strong revenue growth but faces challenges with its net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 7:01 pm

DPZ

Benchmark analyst Todd Brooks has reiterated a Buy rating on Domino's Pizza (NYSE:DPZ) and maintained a price target of $520.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 7:01 pm

MAC

Analysts have provided mixed ratings for Macerich (NYSE:MAC) over the past three months, with a recent increase in the average price target to $15.9. The company's financial performance shows strong profitability and effective cost control, despite challenges in revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 7:01 pm

CC

Analysts have mixed views on Chemours (NYSE:CC), with recent ratings showing a shift towards more conservative price targets. The average 12-month price target has decreased by 14.41% to $25.25. Chemours faces challenges with a 6.39% revenue decline but maintains strong profitability metrics.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 7:01 pm

HUN

Analysts have provided mixed ratings for Huntsman (NYSE:HUN) over the past three months, with a recent downward trend in price targets. The average 12-month price target is now $23.6, down from $25.80. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Huntsman faces challenges in revenue growth and net margin but shows strong return on equity and effective debt management.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 7:00 pm

FOLD

Amicus Therapeutics (NASDAQ:FOLD) received mixed ratings from 4 analysts, with 1 bullish and 3 somewhat bullish ratings. The average 12-month price target is $18.0, down 3.59% from the previous $18.67. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Amicus Therapeutics, a biotechnology company, reported a 34.04% revenue growth rate but faces challenges with a high debt-to-equity ratio and below-average ROE.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 7:00 pm

AMZN

Analysts from Scotiabank and JP Morgan are optimistic about Amazon's future, particularly due to AWS's AI-driven growth. Scotiabank initiated coverage with a 'Sector Outperform' rating and a $245 price target, citing AWS's potential to exceed revenue estimates beyond 2025. JP Morgan also highlights AWS's growth and operational discipline, projecting significant operating income and free cash flow in the coming years.

Portfolio Pulse from Lekha Gupta

October 11, 2024 | 6:59 pm

DPZ

RBC Capital analyst Logan Reich maintains an Outperform rating on Domino's Pizza (NYSE:DPZ) but lowers the price target from $500 to $490.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 6:59 pm